Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BY101298 Combined with Radiotherapy in Solid Tumors
NCT06524804Phase 2Terminated
- Sponsor
- Baiyu Pharmaceutical
- Start
- May 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BY101298 in malignant solid tumor, sponsored by Baiyu Pharmaceutical. Started May 2024; status: terminated.
02
Drugs
BY101298
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT06524804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06524804.